Oral Wegovy’s UK Rollout Puts Novo Nordisk’s Pivot to the Pill to the Test
Novo Nordisk’s long-anticipated shift from injection to tablet enters its most public phase this week, with the oral…
Novo Nordisk Dual Obesity Data and Odense Retooling Signal Strategic Pivot
Novo Nordisk presents promising obesity trial results for high-dose Wegovy and oral semaglutide, while restructuring manufacturing in Odense…
Novo Nordisk’s Strategic Pivot Gains Traction as Clinical Data and Analyst Forecast Align
Novo Nordisk divests last cell therapy asset to double down on obesity; new data shows Wegovy’s 28% weight…
Novo Nordisk’s Profit Surge Masks the Real Story: A Pipeline Pivot Underway
Novo Nordisk beats Q1 earnings estimates, scraps CagriSema combo therapy, raises 2026 guidance, and bets on oral GLP-1…
Novo Nordisk’s Pill Pivot Faces Its First Big Test on Wednesday
Novo Nordisk’s shift to oral GLP-1 drugs faces pricing pressure and Eli Lilly competition as Q1 earnings loom,…
Novo Nordisk’s Strategic Pivot Faces Crucial First-Quarter Test
Novo Nordisk shares down 20% YTD as it faces new oral obesity drug competition from Eli Lilly and…
AI and Aggressive Pricing in a Shifting Market
Novo Nordisk slashes US Wegovy HD price to $399/month, partners with OpenAI for AI integration, and faces generic…
Saudi Cash and Greenland’s Clock Drive Value
European Lithium’s fate hinges on a Greenland permit for Tanbreez rare earths project, despite a strong cash position…
Saudi Cash and Greenland’s Clock Drive Value
European Lithium’s fate hinges on a Greenland permit for Tanbreez rare earths project, despite a strong cash position…
Cash and Greenland Take Center Stage
European Lithium boasts AUD 322M cash, launches buyback. Greenland rare earths project advances with high-grade results, while flagship…
Cash and Greenland Take Center Stage
European Lithium boasts AUD 322M cash, launches buyback. Greenland rare earths project advances with high-grade results, while flagship…
Novo Nordisk Navigates Pricing Pressures with Strategic Pivot
Novo Nordisk slashes prices in some markets and launches Wegovy subscriptions as new clinical data shows edge over…